You are here
Products
FOXL1 Polyclonal
Product group: | Primary |
Monoclonal/ Polyclonal: | Polyclonal |
Host: | Rabbit |
Isotype: | IgG |
Application: | ELISA, Immunohistochemistry (IHC), Western Blot (WB) |
Application notes: | 10-50 |
Conjugation Type: | Unconjugated |
Reactivity: | Human, Mouse, Rat |
General notes: | Localization: nucleus. |
Buffer: | citrate pH6.0 or EDTA pH8.0 |
UNSPSC code: | 12352203 |
Forkhead box protein L1s or FKHL11, is encoded by the FOXL1 gene in human. FOXL1 protein belongs to the forehead box (Fox) family of transcription factors characterized by a common DNA-binding domain (the forkhead box). FOXL1 is involved in regulating the proliferation of gastrointestinal epithelial cells. Loss of Foxl1 leads to distorted architecture of the stomach and small intestine in mice due to a markedly increased epithelial proliferation. Foxl1 knockout is correlated with an enhanced Wnt/β-catenin pathway activation as evidenced by increased β-catenin nuclear localization. FOXL1 expression is down-regulated in the majority of human clear cell renal cell carcinoma (ccRCC), at both mRNA and protein levels. FOXL1 expression inversely correlates with the aggressive phenotype of ccRCC and the survival outcome of patients. (Shipping Cost: €200.00)
FOXL1 Polyclonal
Forkhead box protein L1s or FKHL11, is encoded by the FOXL1 gene in human. FOXL1 protein belongs to the forehead box (Fox) family of transcription factors characterized by a common DNA-binding domain (the forkhead box). FOXL1 is involved in regulating the proliferation of gastrointestinal epithelial cells. Loss of Foxl1 leads to distorted architecture of the stomach and small intestine in mice due to a markedly increased epithelial proliferation. Foxl1 knockout is correlated with an enhanced Wnt/β-catenin pathway activation as evidenced by increased β-catenin nuclear localization. FOXL1 expression is down-regulated in the majority of human clear cell renal cell carcinoma (ccRCC), at both mRNA and protein levels. FOXL1 expression inversely correlates with the aggressive phenotype of ccRCC and the survival outcome of patients.
Alternative names: